No definition available.

Name:	cik0001900520_OwnershipInterestExcess
Namespace Prefix:	cik0001900520_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

Duration of research and development amortized.

No definition available.

Name:	cik0001900520_ResearchAndDevelopmentAmortized
Namespace Prefix:	cik0001900520_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.

Name:	us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

Name:	us-gaap_DeferredTaxAssetsValuationAllowance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.

Name:	us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_IncomeTaxContingencyLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

Lomond Therapeutics Holdings, Inc. 10-K